Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 10;10(8):1935.
doi: 10.3390/biomedicines10081935.

Haematological Drugs Affecting Lipid Metabolism and Vascular Health

Antonio Parrella  1 , Arcangelo Iannuzzi  1 , Mario Annunziata  2 , Giuseppe Covetti  1 , Raimondo Cavallaro  1 , Emilio Aliberti  3 , Elena Tortori  4 , Gabriella Iannuzzo  5
Affiliations
Review

Haematological Drugs Affecting Lipid Metabolism and Vascular Health

Antonio Parrella et al. Biomedicines. .

Abstract

Many drugs affect lipid metabolism and have side effects which promote atherosclerosis. The prevalence of cancer-therapy-related cardiovascular (CV) disease is increasing due to development of new drugs and improved survival of patients: cardio-oncology is a new field of interest and research. Moreover, drugs used in transplanted patients frequently have metabolic implications. Increasingly, internists, lipidologists, and angiologists are being consulted by haematologists for side effects on metabolism (especially lipid metabolism) and arterial circulation caused by drugs used in haematology. The purpose of this article is to review the main drugs used in haematology with side effects on lipid metabolism and atherosclerosis, detailing their mechanisms of action and suggesting the most effective therapies.

Keywords: atherosclerosis; haematological drugs; hypercholesterolemia; hypertriglyceridaemia; lipid metabolism; side effects; vasculopathy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Prevalence of carotid and femoral plaques prior to initiating second- and third-generation tyrosine kinase inhibitors (nilotinib and ponatinib; n = 55).
See this image and copyright information in PMC

References

    1. Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L., Chapman M.J., de Backer G.G., Delgado V., Ference B.A., et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140–205. doi: 10.1016/j.atherosclerosis.2019.08.014. - DOI - PubMed
    1. Ginsberg H.N., Packard C.J., Chapman M.J., Borén J., Aguilar-Salinas C.A., Averna M., Ference B.A., Gaudet D., Hegele R.A., Kersten S., et al. Triglyceride-rich lipoproteins and their remnants: Metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur. Heart J. 2021;42:4791–4806. doi: 10.1093/eurheartj/ehab551. - DOI - PMC - PubMed
    1. Iannuzzo G., Tripaldella M., Mallardo V., Morgillo M., Vitelli N., Iannuzzi A., Aliberti E., Giallauria F., Tramontano A., Carluccio R., et al. Lipoprotein(a) Where Do We Stand? From the Physiopathology to Innovative Terapy. Biomedicines. 2021;9:838. doi: 10.3390/biomedicines9070838. - DOI - PMC - PubMed
    1. Iannuzzi A., Gentile M., Iannuzzo G., Covetti G., Panico C., Mattiello A., La Fata E., D′Elia L., De Michele M., Rubba P. Atherogenic Lipoprotein Subfractions and Carotid Atherosclerosis in Menopausal Women. Angiology. 2018;69:666–671. doi: 10.1177/0003319717744315. - DOI - PubMed
    1. Tziomalos K., Athyros V.G., Karagiannis A., Mikhailidis D.P. Dyslipidemia Induced by Drugs Used for the Prevention and Treatment of Vascular Diseases. Open Cardiovasc. Med. J. 2011;5:85–89. doi: 10.2174/1874192401105010085. - DOI - PMC - PubMed

LinkOut - more resources